Study to Evaluate Safety, Tolerability, and Efficacy of TAK-079 in Participants with Persistent/Chronic Primary Immune Thrombocytopenia

Takeda pharmaceuticals is conducting a multi-centered phase two placebo-controlled double-blinded study to look at the safety, tolerability, and efficacy of a drug called TAK-079, which is a monoclonal antibody (anti-CD38 antibody). The trial is for adult ITP patients whose ITP is persistent or chronic, with a platelet count less than 30,000/µL for four consecutive weeks prior to participating in the trial. TAK-079 would be administered as a subcutaneous injection.

Bulgaria, Croatia, Germany, Greece, Italy, Slovenia, Spain, and USA

Status: Recruiting

back to top

Charity NavigatorGuideStar Seal NORD Member BadgeTHSNA logo